Thông tin thuốc của Apremilast

Thông tin này không áp dụng cho tất cả các quốc gia. Vui lòng tham khảo thông tin kê toa lưu hành tại Việt Nam.

Thông tin thuốc gốc

Chỉ định và Liều dùng

Oral
Psoriatic arthritis

Adult: As monotherapy or in combination with disease-modifying antirheumatic drugs (DMARDs) in patients with active cases who have had an inadequate response or who have been intolerant to previous DMARD therapy: Initial titration schedule: Day 1: 10 mg in the morning. Day 2: 10 mg bid. Day 3: 10 mg in the morning then 20 mg in the evening. Day 4: 20 mg bid. Day 5: 20 mg in the morning then 30 mg in the evening. Day 6 and thereafter (recommended maintenance): 30 mg bid (approx 12 hours apart).

Oral
Plaque psoriasis

Adult: For the treatment of moderate to severe chronic cases in patients who are intolerant to, failed to respond to or who have a contraindication to other systemic therapy or phototherapy: Initial titration schedule: Day 1: 10 mg in the morning. Day 2: 10 mg bid. Day 3: 10 mg in the morning then 20 mg in the evening. Day 4: 20 mg bid. Day 5: 20 mg in the morning then 30 mg in the evening. Day 6 and thereafter (recommended maintenance): 30 mg bid (approx 12 hours apart).

Oral
Oral ulcers associated with Behcet’s disease

Adult: In patients who are candidates for systemic therapy: Initial titration schedule: Day 1: 10 mg in the morning. Day 2: 10 mg bid. Day 3: 10 mg in the morning then 20 mg in the evening. Day 4: 20 mg bid. Day 5: 20 mg in the morning then 30 mg in the evening. Day 6 and thereafter (recommended maintenance): 30 mg bid (approx 12 hours apart).

Suy thận

CrCl (mL/min)	Dosage
<30	Initially, 10 mg once daily in the morning on days 1-3, then titrate (using only the morning doses; skip the evening doses) to 20 mg once daily on days 4-5. Maintenance: 30 mg once daily in the morning beginning on day 6.

Chống chỉ định

Pregnancy and lactation.

Thận trọng

Patient with history of depression and/or suicidal thoughts or behaviour. Patient receiving drugs that may cause volume depletion or hypotension. Underweight patient. Severe renal impairment. Elderly. Concomitant use with strong CYP3A4 inducers is not recommended.

Tác dụng không mong muốn

Significant: Severe diarrhoea, nausea, vomiting; neuropsychiatric effects (e.g. mood changes, suicidal ideation and behaviour, depression); unexplained or clinically significant weight loss.
Gastrointestinal disorders: Dyspepsia, upper abdominal pain, GERD, gastrointestinal haemorrhage.
General disorders and administration site conditions: Fatigue.
Metabolism and nutrition disorders: Decreased appetite.
Musculoskeletal and connective tissue disorders: Back pain.
Nervous system disorders: Headache (including tension headache), migraine.
Psychiatric disorders: Insomnia.
Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection, cough, bronchitis, nasopharyngitis.
Skin and subcutaneous tissue disorders: Rash, urticaria.

Chỉ số theo dõi

Verify pregnancy status in women of childbearing potential before treatment initiation. Monitor weight (regularly during treatment) and renal function. Observe for emergence or worsening of suicidal thoughts, depression, or other mood changes.

Tương tác

Decreased plasma concentration with strong CYP3A4 inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin).

Tương tác với thức ăn

Decreased exposure with St. John's wort.

Tác dụng

Description:
Mechanism of Action: Apremilast, a cyclic adenosine monophosphate (cAMP)-specific phosphodiesterase type-4 (PDE-4) inhibitor, exhibits its effect intracellularly to regulate a network of pro-inflammatory and anti-inflammatory mediators. The inhibition of PDE-4 increases intracellular cAMP levels, which in turn downregulates the inflammatory response by modulating the expression of tumour necrosis factor-α (TNF-α), interleukin (IL)-23, IL-17, and other inflammatory cytokines, and promotes the production of anti-inflammatory mediators, such as IL-10.
Pharmacokinetics:
Absorption: Well absorbed from the gastrointestinal tract. Bioavailability: Approx 73%. Time to peak plasma concentration: Approx 2.5 hours.
Distribution: Volume of distribution: 87 L. Plasma protein binding: Approx 68%.
Metabolism: Extensively metabolised in the liver by non-CYP and CYP-mediated pathways, mainly by the CYP3A4 isoenzyme, including CYP1A2 and CYP2A6 isoenzymes (minor pathways).
Excretion: Via urine (58%; 3% as unchanged drug); faeces (39%; 7% as unchanged drug). Elimination half-life: Approx 6-9 hours.

Đặc tính

Chemical Structure Image — **Apremilast**

Bảo quản

Store below 30°C.

Phân loại MIMS

Thuốc ức chế miễn dịch / Thuốc trị vẩy nến, tăng tiết bã nhờn & vảy cá

Phân loại ATC

L04AA32 - apremilast ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.

Tài liệu tham khảo

Amgen (New Zealand) Limited. Otezla 30 mg Tablets; Otezla Titration Pack 10 mg, 20 mg, 30 mg data sheet 19 October 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 06/01/2022.

Anon. Apremilast. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/01/2022.

Buckingham R (ed). Apremilast. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/01/2022.

Joint Formulary Committee. Apremilast. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/01/2022.

Otezla 10 mg, 20 mg, 30 mg Film-Coated Tablets (Amgen). European Medicines Agency [online]. Accessed 06/01/2022.

Otezla Tablet, Film Coated (Celgene Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/01/2022.

Otezla Tablets (Amgen Biopharmaceuticals Malaysia Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 21/01/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Apremilast từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com